CD4 Mimic Compounds With PEG Side Chains for HIV Entry Inhibition
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current anti-HIV drugs, such as enfuvirtide and maraviroc, can suppress virus proliferation but not completely kill it, leading to long-term administration issues and drug-resistant viruses, while CD4 mimic compounds like NBD-556 have low anti-HIV activity, high cytotoxicity, and low solubility.
Innovation Solution
Development of novel CD4 mimic compounds with PEG or alkyl chains as side chains, such as TKB-001, TKB-002, and TKB-003, to enhance pharmacokinetics, providing longer half-life and reduced cytotoxicity, inhibiting HIV entry by binding to the Phe43-cavity of gp120 and exposing the V3 loop.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current anti-HIV drugs (enfuvirtide, maraviroc) are administered long-term to suppress virus proliferation, then virus suppression is achieved, but drug-resistant viruses emerge and cumulative side effects occur
Solution Approach 1:
The patent creates a small molecule compound that copies the function of the large CD4 protein by mimicking its key interaction features. The compound reproduces the essential binding capability to gp120's Phe43-cavity without requiring the full CD4 structure, thereby achieving HIV entry inhibition with a simplified molecular model that avoids the limitations of protein-based drugs
Solution Approach 2:
The patent optimizes multiple molecular parameters including introducing PEG chains to extend half-life, adjusting molecular weight to 400-800 Da for improved pharmacokinetics, modifying logP values for solubility, and tuning the molecular structure to enhance binding affinity to gp120 while reducing cytotoxicity. These parameter optimizations transform an initially problematic compound into an effective anti-HIV agent
2Reliability
If CD4 mimic compound NBD-556 is used to inhibit HIV entry, then binding to gp120 is achieved, but the compound exhibits low anti-HIV activity, high cytotoxicity, and low solubility
Solution Approach 1:
The patent introduces PEG chains as intermediary structures that mediate between the hydrophobic core of the molecule and the aqueous biological environment. These PEG spacers act as flexible linkers that improve solubility and pharmacokinetic properties while maintaining the essential binding interactions with gp120
Solution Approach 2:
The patent creates composite molecular structures combining hydrophobic aromatic rings for binding affinity, flexible PEG chains for solubility and pharmacokinetics, and basic nitrogen atoms for ionic interactions. This composite approach integrates multiple functional elements into a single molecule that achieves balanced performance across multiple parameters
Data Source
AI summary
CD4 mimic compounds having improved efficacy for anti-HIV treatment and more improved pharmacokinetics are provided. The compounds are represented by formula (I):wherein R1 is C2H4(OC2H4)n—OCH3 or CmH2m+1; R2 is O or NH; n is 3 to 25; and m is 4 to 22, or a salt thereof. HIV infection inhibitor compositions including the compound or a salt thereof as an active ingredient are also disclosed.